Achieving Excellence in Pharmaceutical Care—Different Payment Models
On 1 October 2020, Ilaria was invited as a speaker to the Special Interest Group (SIG) International of the Royal Dutch Pharmacists Association (Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, KNMP).
In response to rising health care costs, ageing population with increased multimorbidity, and avoidable hospitalizations due to adverse drug reactions (ADRs) the role of community pharmacists is becoming increasingly important to counsel patients, ensure a safer use of medicines, improve clinical outcomes, integrate with other health providers, and increase health education among patients.
Many countries face the challenge to better reward community pharmacists for their daily work. In the Netherlands, community pharmacists are remunerated on a fee-for-service basis that funds the number of prescriptions dispensed but does not reward quality.
Alternative payment methods that fund quality-linked interventions by pharmacists—think of patient counseling, improved medicines adherence, the provision of medicines in dose administration aids, etc.—are not yet widespread with few exceptions in North Carolina (USA) and Australia.
Ilaria’s presentation sheds light on alternative payment methods in community pharmacy such as pay-for-performance (P4P) that may reward structure, process, and outcomes with the ultimate goal to improve quality. For more information, please contact email@example.com
How does the lock works in the Netherlands?
We can offer the pharmaceutical industry a better understanding of the Dutch institutional framework, the procedures for market access and reimbursement, the negotiations with hospitals, health insurers but also with the Dutch government when the drug is admitted in the lock system. We can help the industry sharpen their strategy. The Lock (sluis) for new medicines
At the same time we do believe that the current regulation is not working that well but alternatives are difficult to implement. We can offer all parties concerned with the development of new pricing systems to promote innovation but also competitive pricing.